TCR affinity for p/MHC formed by tumor antigens that are self-proteins

Impact on efficacy and toxicity

Jennifer D. Stone, Daniel T. Harris, David M Kranz

Research output: Contribution to journalReview article

Abstract

Recent studies have shown that the range of affinities of T cell receptors (TCRs) against non-mutated cancer peptide/class I complexes are lower than TCR affinities for foreign antigens. Raising the affinity of TCRs for optimal activity of CD8 T cells, and for recruitment of CD4 T cell activity against a class I antigen, provides opportunities for more robust adoptive T cell therapies. However, TCRs with enhanced affinities also risk increased reactivity with structurally related self-peptides, and off-target toxicities. Careful selection of tumor peptide antigens, in silico proteome screens, and in vitro peptide specificity assays will be important in the development of the most effective, safe TCR-based adoptive therapies.

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalCurrent Opinion in Immunology
Volume33
DOIs
StatePublished - Apr 1 2015

Fingerprint

Neoplasm Antigens
T-Cell Antigen Receptor
Peptides
Proteins
T-Lymphocytes
Histocompatibility Antigens Class I
Proteome
Cell- and Tissue-Based Therapy
Computer Simulation
Antigens
Neoplasms

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

TCR affinity for p/MHC formed by tumor antigens that are self-proteins : Impact on efficacy and toxicity. / Stone, Jennifer D.; Harris, Daniel T.; Kranz, David M.

In: Current Opinion in Immunology, Vol. 33, 01.04.2015, p. 16-22.

Research output: Contribution to journalReview article

@article{8d3eef73317249ffb35ed911bbe25e8d,
title = "TCR affinity for p/MHC formed by tumor antigens that are self-proteins: Impact on efficacy and toxicity",
abstract = "Recent studies have shown that the range of affinities of T cell receptors (TCRs) against non-mutated cancer peptide/class I complexes are lower than TCR affinities for foreign antigens. Raising the affinity of TCRs for optimal activity of CD8 T cells, and for recruitment of CD4 T cell activity against a class I antigen, provides opportunities for more robust adoptive T cell therapies. However, TCRs with enhanced affinities also risk increased reactivity with structurally related self-peptides, and off-target toxicities. Careful selection of tumor peptide antigens, in silico proteome screens, and in vitro peptide specificity assays will be important in the development of the most effective, safe TCR-based adoptive therapies.",
author = "Stone, {Jennifer D.} and Harris, {Daniel T.} and Kranz, {David M}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.coi.2015.01.003",
language = "English (US)",
volume = "33",
pages = "16--22",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - TCR affinity for p/MHC formed by tumor antigens that are self-proteins

T2 - Impact on efficacy and toxicity

AU - Stone, Jennifer D.

AU - Harris, Daniel T.

AU - Kranz, David M

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Recent studies have shown that the range of affinities of T cell receptors (TCRs) against non-mutated cancer peptide/class I complexes are lower than TCR affinities for foreign antigens. Raising the affinity of TCRs for optimal activity of CD8 T cells, and for recruitment of CD4 T cell activity against a class I antigen, provides opportunities for more robust adoptive T cell therapies. However, TCRs with enhanced affinities also risk increased reactivity with structurally related self-peptides, and off-target toxicities. Careful selection of tumor peptide antigens, in silico proteome screens, and in vitro peptide specificity assays will be important in the development of the most effective, safe TCR-based adoptive therapies.

AB - Recent studies have shown that the range of affinities of T cell receptors (TCRs) against non-mutated cancer peptide/class I complexes are lower than TCR affinities for foreign antigens. Raising the affinity of TCRs for optimal activity of CD8 T cells, and for recruitment of CD4 T cell activity against a class I antigen, provides opportunities for more robust adoptive T cell therapies. However, TCRs with enhanced affinities also risk increased reactivity with structurally related self-peptides, and off-target toxicities. Careful selection of tumor peptide antigens, in silico proteome screens, and in vitro peptide specificity assays will be important in the development of the most effective, safe TCR-based adoptive therapies.

UR - http://www.scopus.com/inward/record.url?scp=84921479955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921479955&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2015.01.003

DO - 10.1016/j.coi.2015.01.003

M3 - Review article

VL - 33

SP - 16

EP - 22

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

ER -